Nexavar case may spawn more India compulsory licensing activity in oncology/HIV areas
This article was originally published in Scrip
India's recent decision granting a compulsory licence for Bayer's anticancer Nexavar (sorafenib tosylate) to Natco Pharma may theoretically open the flood gates to several more applications, especially in the oncology and HIV/AIDS segments. But legal experts believe that the controversial interpretation of "working" an invention to include local manufacture may be challenged all the way to the country's top court or even at the World Trade Organisation (WTO).
You may also be interested in...
Scrip traces some of the prominent changes in the corner office at front-line, family-owned Indian firms Cipla and Dr Reddy’s in the decade gone by.
Glenmark has struck a deal with private equity firm True North for its gynecology business in India and Nepal.
Draft policy moots crowdfunding for high-cost rare diseases alongside financial support for those "amenable to one-time treatment" but falls way short of some patient groups' expectations.